We hope that this study, which included proteomic studies of OCT3 in the human BBB, as well as new ligands for this transporter has added to the body of work of Professor Emerita Margareta Hammarlund-Udenaes who is a pioneer in BBB research in the pharmaceutical sciences (61–63), and to the concepts and methodologies in improving treatment of neurological diseases (64). Here, SLC22A3 is linked to nervous system disorder.